Alkermes shares are trading lower. The company reported Q2 financial results.benzinga_article·2 days ago, 08:20 AMALKS+3.50%
ALKS: Q2 2026 revenue and profitability surged following the Avadel acquisition and product growthQuartr·2 days ago, 06:47 AMALKS+3.50%AVDL0.00%
Alkermes reports Q2 2026 revenue $496.0M, GAAP net income $0.5M, Adjusted EBITDA $139.2MTradingView·2 days ago, 06:13 AMALKS+3.50%AVDL0.00%
Alkermes plc $ALKS Shares Bought by Knott David M JrMarket Beat·Jul 24 at 05:10 AMALKS+3.50%UBS+3.07%
Alkermes Says Lead Drug Maintains Wakefulness Benefits in Long-Term Narcolepsy Studybenzinga_article·Jul 13 at 10:06 AMALKS+3.50%
Alkermes says alixorexton sustains wakefulness gains in nine-month narcolepsy extension study interim analysisPUBT·Jul 13 at 06:01 AMALKS+3.50%
Alkermes Ends Generic VIVITROL Supply Agreement with AmnealTip Ranks·Jul 8 at 07:30 AMAMRX-3.14%ALKS+3.50%
Alkermes EVP, CLO David Joseph Gaffin sells 2,034 shares for $109,882.02PUBT·Jul 6 at 03:49 PMALKS+3.50%
Corient Private Wealth LLC Trims Position in Alkermes plc $ALKSMarket Beat·Jul 5 at 02:20 AMALKS+3.50%UBS+3.07%
The Bull Case For Alkermes (ALKS) Could Change Following Vibrance-12 Data And Russell 2000 InclusionSimplywall·Jul 4 at 03:16 AMALKS+3.50%
